glp-1 side effect class action in louisiana Novo Nordisk is suing Eli Lilly over its ads, accusing the rival drugmaker of false advertising for claiming Lilly's Mounjaro and Zepbound outperform Novo's Ozempic and Wegovy. MORE BELOW ⬇️ Louisiana spent over $1B on

The most common mistake semaglutide users make with probiotics is treating timing as an afterthought, popping capsules whenever they remember without considering how the probiotic interacts with their injection schedule, meals, and other supplements

While berberine has shown some promise in managing type 2 diabetes and weight loss, its effectiveness is limited due to poor absorption in the intestines

This raises the possibility that GLP-1 agonists could be used in combination with existing treatments for OUD to improve outcomes for individuals trying to quit opioid use

One more time for clarity: This supplement does not contain pharmaceutical GLP-1 receptor agonists

Theres already some existing evidence to suggest GLP-1s reduce cravings, whether its alcohol, food, or even drugs